Mycovia Pharmaceuticals

Biopharmaceutical company formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. Commercializes VIVJOA® (oteseconazole), the first and only FDA-approved medication to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in post-menopausal women.